ARTES Biotech and Burnet Institute join forces to develop Hep C vaccine
Australia’s largest virology and communicable disease research institute and a German biotech company have joined forces in a bid to develop a vaccine that prevents transmission of hepatitis C virus (HCV).
The Burnet Institute and ARTES Biotechnology made the announcement earlier today.
The project will combine Burnet's proprietary HepSeeVaxDelta3 technology with ARTES’ proprietary METAVAX technology for the development of chimeric virus-like particle (VLP) based vaccines. The VLPs will present the novel, modified envelope protein (E2) on its surface, thereby targeting the vaccine to dendritic cells to prime and prepare the immune system to fight against hepatitis C infection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze